NSPR News and Press, InspireMD Inc. From 01/31/24

TEL AVIV, Israel and MIAMI, Jan. 31, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Carotid Stent System (EPS) for the prevention of stroke, today announced that it has received CE Mark recertification under the European Union’s ...

Appointment brings more than 30 years of medical technology general management and commercial leadership experience to the InspireMD team Reports inducement grant under NASDAQ listing rule 5635(c)(4) TEL AVIV, Israel and MIAMI, Jan. 03, 2024 (GLOBE NEWSWIRE) -- InspireMD (Nasdaq: ...

TEL AVIV, Israel and MIAMI, Dec. 20, 2023 (GLOBE NEWSWIRE) -- InspireMD (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, announced today the issuance of U.S. Patent No. 11,844,893, titled, “Shunts with Blood Flow Indicators...

2023-12-04 16:43:39 ET More on InspireMD InspireMD Inc. (NSPR) Q3 2023 Earnings Call Transcript InspireMD Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on InspireMD For further details see: InspireMD says Roubin buys 50K shares in co

TEL AVIV, Israel and MIAMI, Nov. 27, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that the company has entered into a strategic agreement with the Jacobs Institute at th...

2023-11-06 11:09:13 ET InspireMD Inc. (NSPR) Q3 2023 Results Earnings Conference Call November 6, 2023, 08:30 AM ET Company Participants Charles Padala - Investor Relations, LifeSci Advisors Marvin Slosman - President, CEO and Director Craig Shore - Chief Financi...

2023-11-06 07:08:45 ET More on InspireMD Seeking Alpha’s Quant Rating on InspireMD Historical earnings data for InspireMD Financial information for InspireMD For further details see: InspireMD GAAP EPS of -$0.15 misses by $0.01, revenue of $1.56M b...

CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...

InspireMD Inc. (NSPR) is expected to report $-0.17 for Q3 2023

2023-11-05 11:08:50 ET Major earnings expected before the bell on Monday include: Axsome Therapeutics ( AXSM ) Brookfield Asset Management ( BAM ) BioNTech ( BNTX ) Ceragon Networks ( CRNT ) DISH Network ( DISH ) For further details see: N...